Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)

Breast Cancer Res Treat. 2018 Jun;169(3):537-548. doi: 10.1007/s10549-018-4713-2. Epub 2018 Feb 17.

Abstract

Purpose: Aromatase inhibitors are the most commonly prescribed adjuvant endocrine therapy for hormone-dependent early breast cancer in postmenopausal women. Among Canadian Cancer Trials Group MA.27 participants, anastrozole and exemestane had comparable 5-year event-free survival. This companion study examined differences in patient-reported treatment-related symptoms (TRS) and health-related quality of life (HRQL) among postmenopausal women randomized to anastrozole or exemestane.

Methods: MA.27 participants (N = 686, of 7576) randomized to 5 years of anastrozole (1 mg/day, n = 371, Arm A) or exemestane (25 mg/day, n = 315, Arm E) completed the 56-item Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES) questionnaire to assess TRS and HRQL. The FACT-ES was completed at baseline, 3, 6, 12, and 24 months.

Results: No significant differences in FACT-ES median scores measuring TRS and HRQL were observed between treatment arms at any time point. Change in TRS from baseline was statistically significant at 3, 6, 12, and 24 months. HRQL was stable over time in both arms. Greater TRS burden was associated with poorer HRQL (coefficient = 0.57, p < 0.001). Twenty percent of patients discontinued AI therapy by month 24 and 32% discontinued AIs at 4 years. In both arms, patients reporting more side effect bother prior to initiating study treatment had a higher risk of discontinuing treatment before completing protocol therapy (hazard ratio [HR] 1.29, 95% CI 1.08-1.55, p = 0.01).

Conclusions: TRS and HRQL were comparable between anastrozole and exemestane. TRS negatively affect HRQL. Women who report being bothered by treatment side effects prior to initiating an AI are at increased risk for early treatment discontinuation.

Keywords: Endocrine therapy adherence; Patient-reported outcomes; Quality of life; Tolerability; Treatment-related symptoms.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anastrozole / administration & dosage
  • Anastrozole / adverse effects
  • Anastrozole / therapeutic use
  • Androstadienes / administration & dosage
  • Androstadienes / adverse effects
  • Androstadienes / therapeutic use
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / epidemiology*
  • Breast Neoplasms / mortality
  • Combined Modality Therapy
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Medication Adherence*
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Patient Reported Outcome Measures
  • Postmenopause
  • Quality of Life*
  • Randomized Controlled Trials as Topic

Substances

  • Androstadienes
  • Anastrozole
  • exemestane